All Interventions

    Survodutide

    Pharmaceuticals
    GLP-1/Glucagon Dual Agonists

    Survodutide is an investigational once-weekly dual GLP-1/glucagon receptor agonist from Boehringer Ingelheim. By pairing GLP-1 appetite and glycemic effects with glucagon-driven hepatic fat oxidation, it preferentially targets liver and visceral fat. Positive Phase 3 results in obesity (SYNCHRONIZE-1) and at-risk MASLD (SYNCHRONIZE-MASLD) were reported in 2026.

    Evidence Summary

    7
    / 10Score
    Moderate
    Moderate Evidence

    Phase 3 results (2026) now support the earlier Phase 2 signal. In SYNCHRONIZE-1 (NEJM 2026; 725 adults with obesity without diabetes, 76 weeks), once-weekly survodutide 6.0 mg reduced body weight by up to 16.6% vs ~3.2% with placebo (efficacy estimand); a pre-specified MRI substudy showed ~34% relative reduction in visceral fat and ~63% reduction in liver fat. In SYNCHRONIZE-MASLD (Nature Medicine 2026; 216 adults with obesity and at-risk MASLD, 48 weeks), 84.2% of survodutide-treated patients achieved >=30% reduction in liver fat vs 24.3% with placebo, with ~12.2% weight loss vs 1.0%. The Phase 2 MASH trial (NEJM 2024) had shown MASH improvement without worsening fibrosis in up to 83% of patients (vs 18.2% placebo) and fibrosis improvement in 52.3% (vs 25.8%). Gastrointestinal effects (nausea, diarrhea, vomiting) were the most common adverse events, mostly during dose escalation. Survodutide remains investigational and is not yet approved.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    Dual agonism of the GLP-1 and glucagon receptors. The GLP-1 component reduces appetite and improves glycemia; glucagon-receptor activation uniquely drives hepatic lipid oxidation, increases energy expenditure, and promotes thermogenesis, preferentially reducing liver and visceral fat.

    Who Is This For?

    Expected: NASH/MAFLD, obesity. May be particularly suited for patients with metabolic syndrome and hepatic steatosis.

    Protocol & Dosing

    Dose

    Phase 3 dose: once-weekly subcutaneous survodutide titrated to 6.0 mg (a 3.6 mg arm was also studied). Final labeled dose pending regulatory approval.

    Frequency

    Weekly injection (anticipated)

    Duration

    Ongoing (anticipated)

    Protocol Summary

    Dual GLP-1/glucagon receptor agonist, once-weekly subcutaneous, titrated to 6.0 mg. The Phase 3 program (SYNCHRONIZE-1 in obesity and SYNCHRONIZE-MASLD in at-risk MASLD) completed in 2026 with positive efficacy. Differentiated from GLP-1/GIP agents such as tirzepatide by a glucagon arm that drives hepatic lipid oxidation and preferentially targets liver and visceral fat. Not yet approved; dosing and clinical availability pending regulatory review.

    Interactions & Precautions

    Contraindications

    • Not fully established
    • Likely thyroid warnings per GLP-1 class
    • Active liver disease requiring monitoring

    Potential Risks

    • •Glucagon-mediated cardiac effects
    • •Transaminase elevations
    • •Long-term safety data pending

    Potential Side Effects

    Nausea
    Diarrhea
    Vomiting
    Increased heart rate
    Transaminase elevations

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Differentiated from tirzepatide (GLP-1/GIP) by its glucagon arm, which preferentially mobilizes liver and visceral fat; Phase 3 MRI data show ~63% liver-fat and ~34% visceral-fat reduction. Monitor transaminases and heart rate. Not yet approved or clinically available - this is a summary of published research, not a treatment recommendation.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Latest Evidence

    2024-2026: survodutide's first Phase 3 readouts

    Survodutide is a once-weekly dual GLP-1/glucagon receptor agonist, and 2024-2026 brought its first large Phase 3 results. In SYNCHRONIZE-1 (New England Journal of Medicine, 2026; 725 adults with obesity without diabetes, 76 weeks), survodutide 6.0 mg reduced body weight by up to 16.6% versus about 3.2% with placebo. A pre-specified MRI substudy showed the glucagon component's signature effect on fat distribution: roughly 34% relative reduction in visceral fat and about 63% reduction in liver fat, with most of the lost tissue being fat rather than lean mass.

    The liver story deepened in SYNCHRONIZE-MASLD (Nature Medicine, 2026; 216 adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease, 48 weeks), where 84.2% of survodutide-treated patients achieved at least a 30% reduction in liver fat versus 24.3% on placebo, alongside about 12.2% weight loss. These build on the Phase 2 MASH trial (NEJM, 2024), in which up to 83% of patients had MASH improvement without worsening fibrosis and liver scarring improved in 52.3% versus 25.8% on placebo. What sets survodutide apart from GLP-1/GIP agents such as tirzepatide is the glucagon arm, which drives hepatic lipid oxidation and energy expenditure.

    Survodutide is investigational and is not approved or clinically available; Phase 3 efficacy is promising but long-term outcome and safety data are still maturing, and the most common side effects are gastrointestinal (nausea, diarrhea, vomiting), mainly during dose escalation. These are summaries of published research, not treatment claims. Educational information, not medical advice - discuss any GLP-1-based therapy with a qualified clinician. Peak Human does not sell or provide survodutide.

    Phase 3 SYNCHRONIZE-1 · 725 adults · 76 weeks · obesity without diabetes

    Survodutide 6.0 mg vs placebo - weight, visceral & liver fat

    Taller bar = greater reduction ↑

    Source: SYNCHRONIZE-1, New England Journal of Medicine (2026); 725 adults with obesity without diabetes, 76 weeks, survodutide 6.0 mg once weekly. The body-weight figure is the efficacy estimand; visceral- and liver-fat values are relative reductions from the pre-specified MRI substudy reported at ADA 2026. Survodutide is investigational and not approved. Educational summary of published research, not a treatment claim.

    Key references: Survodutide once weekly for the treatment of adults with obesity (SYNCHRONIZE-1) - New England Journal of Medicine (2026) · Survodutide in adults with obesity and MASLD (SYNCHRONIZE-MASLD) - Nature Medicine (2026) · A phase 2 randomized trial of survodutide in MASH and fibrosis - New England Journal of Medicine (2024) · Pharmacotherapies for liver fibrosis in MASLD F1-F3: network meta-analysis - Journal of Translational Medicine (2026)

    Cost & Access

    Cost Range

    TBD

    Accessibility

    Not yet available - Phase 3 complete (2026); not yet approved

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation